Oncoteq in-licenses a promising pre-clinical breast cancer candidate

Oncoteq, a company founded and seeded by Cureteq and headquartered in Zug, Switzerland, today announced its second in-licensing deal as it obtains a world-wide exclusive license to a novel compound with potential to shift the paradigm in breast cancer treatment.

The first-in-class compound TEQ103 (formerly SERA2) is a selective estrogen receptor activator, which specifically targets cancer cells expressing estrogen receptor alpha and in mouse models induces complete regression of tumors that are resistant to current treatments.

Although Oncoteq did not reveal the name of the licensor, SERA2 is the development code for USA-based Systems Oncology’s next generation estrogen receptor positive drug candidate, for which pre-clinical data were presented at the J P Morgan conference in December last year.